TAT-OSBP-1-MKK6(E)

TAT-OSBP-1-MKK6(E) is a **novel cell-penetrating fusion protein** designed for targeted anti-tumor activity, particularly against human ovarian cancer. It comprises three engineered domains: - An HIV-1 TAT peptide sequence (YGRKKRRQRRR) that enables cell membrane transduction, allowing the fusion protein to enter cells efficiently. - An OSBP-derived domain (Oxysterol-binding protein fragment) to provide specific cell targeting. - A constitutively active mutant of human MKK6 (also known as MAP2K6), referred to as MKK6(E), which specifically activates the p38/MAPK pathway. Activation of this pathway by constitutively active MKK6(E) induces **autophagic cell death** in cancer cells, inhibits proliferation, reverses cisplatin resistance, and selectively targets ovarian cancer cells. Mechanistically, TAT-OSBP-1-MKK6(E) enables intracellular delivery and selective activity in cancer cells, leading to apoptosis or autophagic cell death through persistent activation of the p38/MAPK pathway. This mechanism suggests potential for this agent as a chemotherapeutic, especially in cisplatin-resistant ovarian cancer[1][2][3][4][5][6].

Other names

TAT-OSBP-MAP2K6(E)TAT-OSBP1-1-MKK6(E)TAT-OSBP-1-MKK6(e)